NCT03946800: A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 101 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a solid tumor that expresses EGFR; Patients must have progressed on or refractory to at least 1 line of standard systemic therapy in the recurrent/metastatic setting
Exclusions: Patients with untreated symptomatic central nervous system (CNS) metastases

Comments are closed.

Up ↑